辛伐他汀对腹型肥胖患者NAFLD发病率的影响及其机制  

Effect and Mechanism of Simvastatin on the Incidence of NAFLD in Patients with Abdominal Obesity

作　　者：詹海勇[1] 黄聪武[1] 

机构地区：[1]汕头大学医学院第二附属医院消化内科,广东汕头515041

出　　处：《中国医药指南》2011年第18期182-183,共2页Guide of China Medicine

摘　　要：目的探讨辛伐他汀对腹型肥胖患者NAFLD发病率的影响及其机制。方法收集86例腹型肥胖合并血浆高敏-C反应蛋白(Hs-CRP)升高患者,随机分为对照组(安慰剂10mg/qn,口服)和治疗组(辛伐他汀10mg/qn,口服),每3个月随访一次,评估两组患者NAFLD发病率、血浆ALT、AST、GGT、Hs-CRP、TG和TC水平,共随访1年;同时分析血浆Hs-CRP水平与NAFLD发病率间的关系。结果随访1年后,与对照组相比,治疗组患者NAFLD发病率较低(16.3%vs 32.6%,P<0.05),且血浆Hs-CRP水平也较低(2.3±0.4mmol/L vs 3.7±0.6mmol/L,P<0.05);Pearson相关分析结果提示NAFLD发病率与血浆Hs-CRP水平呈正相关(r=0.877,P<0.05)。结论辛伐他汀能够降低腹型肥胖患者NAFLD的发病率,其机制可能与辛伐他汀下调血浆Hs-CRP水平有关。Objective To investigate the effect and mechanism of simvastatin on the incidence of non-alcoholic fatty liver disease（NAFLD） in patients with abdominal obesity.Method Eighty-six abdominal obesity patients with serum high sensitivity C-reactive protein（Hs-CRP） elevation were enrolled and were randomly assigned into control group（placebo10mg/qn,p.o.） and therapeutic group（simvastatin 10mg/qn,p.o.）.The incidence of NAFLD and the serum levels of ALT,AST,GGT,Hs-CRP,TG and TC were detected trimonthly and totally for one year follow up.The relationship between serum level of Hs-CRP and incidence of NAFLD was also analysed.Results After one year＇s follow up,comparing to control group,the incidence of NAFLD was lower in therapeutic group（16.3%vs 32.6%,P〈0.05）and serum level of Hs-CRP was also lower in therapeutic group（2.3±0.4mmol/L vs 3.7±0.6mmol/L,P〈0.05）.The correlation coefficient between serum level of Hs-CRP and incidence of NAFLD was positive as analysing by Pearson correlation analysis（r=0.877,P〈0.05）.Conclusion Incidence of NAFLD in abdominal patients could be reduced by simvastatin therapy and the mechanism may be ascribed to the down-regulation of serum level of Hs-CRP with simvastatin therapy.

关 键 词：辛伐他汀 腹型肥胖 非酒精性脂肪性肝病 

分 类 号：R575.5[医药卫生—消化系统]